Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis

Actas Dermosifiliogr. 2014 Oct;105(8):802-3. doi: 10.1016/j.ad.2013.09.013. Epub 2013 Dec 17.

[Article in English, Spanish]

Authors

N Knöpfel¹, A Martín-Santiago², A Bauza¹, J A Hervás³

Affiliations

¹ Servicio de Dermatología, Hospital Universitario Son Espases, Palma de Mallorca, España.
² Servicio de Dermatología, Hospital Universitario Son Espases, Palma de Mallorca, España. Electronic address: [email protected].
³ Instituto Universitario de Ciencias de la Salud-IUNICS, Universidad de las Islas Baleares, Palma de Mallorca, España.

PMID: 24355193
DOI: 10.1016/j.ad.2013.09.013

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Topical
Adolescent
Angiofibroma / drug therapy*
Antibiotics, Antineoplastic / administration & dosage*
Facial Neoplasms / drug therapy*
Humans
Hypopigmentation / drug therapy*
Hypopigmentation / etiology
Male
Neoplasms, Multiple Primary / drug therapy*
Sirolimus / administration & dosage*
Tuberous Sclerosis / complications*

Substances

Antibiotics, Antineoplastic
Sirolimus